PharmaCyte Biotech, Inc.
PMCB
$1.64
-$0.12-6.82%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -106.27% | 1,639.17% | 317.38% | -122.21% | 187.64% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 103.61% | -1,253.88% | -676.07% | 107.27% | -245.72% |
| Change in Net Operating Assets | -457.44% | 44.32% | -35.81% | 124.47% | -187.95% |
| Cash from Operations | -182.53% | -12.10% | -88.03% | 91.08% | -678.54% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | 100.00% | -- | -- |
| Cash from Investing | 100.00% | -- | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -89.10% | 36.81% | -193.14% | -142.85% | 99.38% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | 0.98% | 0.97% | -43.45% | -391.75% | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | -5.59% | 4.91% | -51.97% | -1,040.15% | -88.08% |
| Foreign Exchange rate Adjustments | -50.00% | 150.00% | -136.36% | 168.75% | -420.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.77% | -59.06% | 9.70% | -887.22% | -118.68% |
